Clinical Trials

378 enrolled 15 charts 1 FDA

Uveal Melanoma, Melanoma

NCT03914612 2026-03-17

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

813 enrolled 16 charts 1 FDA

GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT03142334 2026-03-10

KEYNOTE-564

994 enrolled 10 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT05116189 2026-03-09

KEYNOTE-B96

643 enrolled 17 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02362594 2026-03-05

MK-3475-054

1,019 enrolled 16 charts 1 FDA

Melanoma

NCT02811861 2026-02-23

CLEAR

1,069 enrolled 12 charts 1 FDA

Carcinoma, Renal Cell

NCT04221945 2026-02-20

KEYNOTE-A18

1,060 enrolled 30 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT03635567 2026-02-04

KEYNOTE-826

617 enrolled 29 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT02853331 2026-02-02

KEYNOTE-426

861 enrolled 24 charts 1 FDA

Carcinoma, Renal Cell

NCT03390504 2026-02-02

THOR

629 enrolled 32 charts 1 FDA

Urothelial Cancer

NCT05722015 2025-09-11

MK-3475A-D77

377 enrolled 17 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03765918 2025-08-20

MK-3475-689

714 enrolled 90 charts 1 FDA

Head & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Head and Neck Neoplasms

NCT02358031 2025-07-18

MK-3475-048

882 enrolled 50 charts 1 FDA

Head & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Head and Neck Neoplasms

NCT03517449 2025-06-15

MK-3475-775

827 enrolled 18 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT04223856 2025-06-13

EV-302

886 enrolled 12 charts 1 FDA

Urothelial Cancer

NCT04003636 2025-04-23

KEYNOTE-966

1,069 enrolled 19 charts 1 FDA

138 enrolled 34 charts 2 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT03665597 2025-02-10

KEYNOTE-555

Phase 1 Completed

520 enrolled 16 charts 1 FDA

Melanoma

NCT02784171 2024-12-10

Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma

Phase 2/3 Completed

Other solid neoplasmThoracic

Mesothelioma

NCT03425643 2024-12-03

MK-3475-671

797 enrolled 23 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03553836 2024-11-29

KEYNOTE-716

976 enrolled 15 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT02819518 2024-11-27

KEYNOTE-355

882 enrolled 41 charts 2 FDA

Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT03189719 2024-10-15

KEYNOTE-590

749 enrolled 40 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT02775435 2024-10-08

KEYNOTE-407

559 enrolled 18 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT02563002 2024-10-03

KEYNOTE-177

307 enrolled 16 charts 2 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT02578680 2024-09-20

MK-3475-189

616 enrolled 19 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT02702414 2024-09-04

KEYNOTE-224

156 enrolled 17 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Hepatocellular

NCT03284424 2024-08-23

MK-3475-629

159 enrolled 16 charts 2 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Squamous Cell

NCT02054806 2023-10-30

MK-3475-028

Phase 1 Completed

477 enrolled 14 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT02220894 2023-10-10

Keynote 042

1,274 enrolled 23 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT02576990 2023-07-27

MK-3475-170

80 enrolled 19 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT02501096 2023-07-20

A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors

Phase 1/2 Completed

357 enrolled 28 charts 1 FDA

Tumor-Agnostic

Neoplasms

NCT02267603 2023-07-05

Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer

50 enrolled 11 charts 1 FDA

Carcinoma, Merkel Cell

NCT02564263 2023-03-13

KEYNOTE-181

628 enrolled 27 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT02559687 2022-09-14

KEYNOTE-180

121 enrolled 14 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT02335411 2022-08-08

KEYNOTE-059

318 enrolled 24 charts 1 FDA